Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

第3相 実施中（募集終了） NCT01272037

概要

This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in the breast to surrounding normal tissue (invasive). Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective with combination chemotherapy in treating patients with breast cancer.

Invasive Disease-Free Survival (IDFS)

5 years after randomization · percentage of participants

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Vitamin D and Physical Activity on Bone Health — University of Rochester
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor — National Cancer Institute (NCI)
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced — National Cancer Institute (NCI)
• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Can — AstraZeneca
• Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Adm — University of Colorado, Denver
• Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer — National Cancer Institute (NCI)

すべての治験